Hoya News
Print this Article | Send to Colleague
HOYA Vision Care Wins Prestigious Silmo d’Or Award in Paris
MiYOSMART, a spectacle lens that manages myopia, takes first prize in the Vision category
HOYA Vision Care is proud to announce that its MiYOSMART lens has won the highly regarded Silmo d’Or Award in the Vision category at the recent Silmo Paris Optical Fair. The spectacle lens was developed to address and manage myopia in children through years of partnership with the Hong Kong Polytechnic University and launched in Hong Kong and the Peoples Republic of China in 2018.
Myopia, or nearsightedness, is a growing global health concern, with nearly 50% of the world’s population expected to be impacted by 2050. The MiYOSMART lens, an easy to use, non-invasive treatment to control myopia, has been shown to slow the progress on average by 60% based on results from a two-year clinical trial published in the British Journal of Ophthalmology.1
“Innovation and collaboration to bring the best solutions to Eye Care Professionals and their patients is at the core of HOYA Vision Care’s mission,” said Alexandre Montague, CEO HOYA Vision Care. “It is an honor to be recognized by our peers receiving the Silmo d’Or Award for our ground-breaking MiYOSMART lens which is successfully managing and controlling myopia in children.”
MiYOSMART was previously awarded the Grand Prize, Grand Award and Gold Medal at the 46th International Exhibition of Inventions of Geneva in April 2018. The lens with its patent protected Defocus Incorporated Multiple Segments (DIMS) Technology provides both sharp vision and a treatment effect to children. Due to hundreds of small defocus islands, these lenses are designed to curb myopia progression by utilizing myopic defocus. The unique structure of the lens allows it to be used in combination with any type of frame, appearing as a regular lens.
After launching MiYOSMART in several Asian markets, Canada and Australia, HOYA Vision Care began the roll out of the MiYOSMART lens in Europe in 2020, starting in France.
MiYOSMART has not been approved for use in the treatment of Myopia in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S. We are currently seeking guidance from the FDA to better understand the approval pathways before we can speculate on the timing for a U.S. launch.
1 Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739
